Comparison of the in vitro activities of quassinoids with activity against Plasmodium falciparum, anisomycin and some other inhibitors of eukaryotic protein synthesis. 1990

R M Ekong, and G C Kirby, and G Patel, and J D Phillipson, and D C Warhurst
Department of Medical Parasitology, London School of Hygiene and Tropical Medicine, U.K.

Using the inhibition of incorporation of [3H]hypoxanthine as an index of viability of malaria parasites, it was shown that a chloroquine-sensitive strain of Plasmodium falciparum (T9-96) and a chloroquine-resistant strain (K1) did not differ in their sensitivities to the quassinoids ailanthinone, bruceantin and chaparrin. Similarly, there were no differences between the strains in their sensitivities to the protein synthesis inhibitors anisomycin, deacetylanisomycin, cephalotaxine, homoharringtonine, cycloheximide, puromycin and puromycin aminonucleoside. The IC50 values derived for ailanthinone and bruceantin, cycloheximide, homoharringtonine and puromycin were in the nanomolar range, whereas those for the anisomycins, cephalotaxine and the aminonucleoside of puromycin were micromolar or greater. Those drugs tested which contain an ester moiety (ailanthinone, bruceantin, anisomycin, homoharringtonine) were more active than the related drugs (chaparrin, deacetylanisomycin, cephalotaxine) that do not. Cross-resistance to inhibitors of protein synthesis appeared not to accompany resistance to chloroquine.

UI MeSH Term Description Entries
D010963 Plasmodium falciparum A species of protozoa that is the causal agent of falciparum malaria (MALARIA, FALCIPARUM). It is most prevalent in the tropics and subtropics. Plasmodium falciparums,falciparums, Plasmodium
D011500 Protein Synthesis Inhibitors Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. Protein Synthesis Antagonist,Protein Synthesis Antagonists,Protein Synthesis Inhibitor,Antagonist, Protein Synthesis,Antagonists, Protein Synthesis,Inhibitor, Protein Synthesis,Inhibitors, Protein Synthesis,Synthesis Antagonist, Protein,Synthesis Inhibitor, Protein
D011691 Puromycin A cinnamamido ADENOSINE found in STREPTOMYCES alboniger. It inhibits protein synthesis by binding to RNA. It is an antineoplastic and antitrypanosomal agent and is used in research as an inhibitor of protein synthesis. CL-13900,P-638,Puromycin Dihydrochloride,Puromycin Hydrochloride,Stylomycin,CL 13900,CL13900,P 638,P638
D011759 Pyrrolidines Compounds also known as tetrahydropyridines with general molecular formula (CH2)4NH. Tetrahydropyridine,Tetrahydropyridines
D002738 Chloroquine The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses. Aralen,Arechine,Arequin,Chingamin,Chlorochin,Chloroquine Sulfate,Chloroquine Sulphate,Khingamin,Nivaquine,Sulfate, Chloroquine,Sulphate, Chloroquine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000841 Anisomycin An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system. Flagecidin
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

R M Ekong, and G C Kirby, and G Patel, and J D Phillipson, and D C Warhurst
May 1981, The American journal of tropical medicine and hygiene,
R M Ekong, and G C Kirby, and G Patel, and J D Phillipson, and D C Warhurst
June 1996, Farmaco (Societa chimica italiana : 1989),
R M Ekong, and G C Kirby, and G Patel, and J D Phillipson, and D C Warhurst
December 1989, Biochemical pharmacology,
R M Ekong, and G C Kirby, and G Patel, and J D Phillipson, and D C Warhurst
March 2005, Cancer letters,
R M Ekong, and G C Kirby, and G Patel, and J D Phillipson, and D C Warhurst
April 1995, Planta medica,
R M Ekong, and G C Kirby, and G Patel, and J D Phillipson, and D C Warhurst
January 1994, The Journal of eukaryotic microbiology,
R M Ekong, and G C Kirby, and G Patel, and J D Phillipson, and D C Warhurst
June 1999, Antimicrobial agents and chemotherapy,
R M Ekong, and G C Kirby, and G Patel, and J D Phillipson, and D C Warhurst
March 2006, Bioorganic & medicinal chemistry,
R M Ekong, and G C Kirby, and G Patel, and J D Phillipson, and D C Warhurst
January 1990, Transactions of the Royal Society of Tropical Medicine and Hygiene,
R M Ekong, and G C Kirby, and G Patel, and J D Phillipson, and D C Warhurst
January 1989, The American journal of tropical medicine and hygiene,
Copied contents to your clipboard!